Gene Switch Market Report 2024

This Gene Switch market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The gene switch market size has grown rapidly in recent years. It will grow from $0.72 billion in 2023 to $0.82 billion in 2024 at a compound annual growth rate (CAGR) of 14.1%. The increase observed during the historical period can be linked to the expansion of gene-based clinical trials, advancements in regenerative medicine, growing public awareness of genetic technologies, broader research in functional genomics, and a rising demand for genetic testing services.

The gene switch market size is expected to see rapid growth in the next few years. It will grow to $1.39 billion in 2028 at a compound annual growth rate (CAGR) of 14.2%. The projected growth during the forecast period can be attributed to the growing need for personalized medicine, a higher prevalence of genetic disorders, an increased demand for targeted cancer therapies, global health initiatives, and the rising use of gene switches. Key trends expected in the forecast period include advancements in technology, CRISPR-based gene switches, AI integration, the adoption of gene switches for gene silencing, and epigenetic gene switches.

The growing prevalence of genetic disorders is anticipated to boost the gene switch market in the future. Genetic disorders arise from abnormalities in an individual's DNA, which can result from mutations, inherited genetic changes, or chromosomal anomalies. This increase in genetic disorders is largely due to greater awareness, enhanced diagnostic capabilities, better healthcare, and an aging population. Gene switches offer a significant advantage in managing these disorders by allowing precise control over gene expression, thereby fostering the development of targeted and effective treatments. For instance, in September 2023, the Cystic Fibrosis Trust, a UK-based national charity, reported an increase in registered cystic fibrosis patients in the UK from 10,908 in 2021 to 11,148 in 2022, marking a rise of 240 patients. Consequently, the increasing incidence of genetic disorders is fueling growth in the gene switch market.

The growing adoption of personalized medicine is expected to drive the expansion of the gene switch market. Personalized medicine customizes medical treatments based on individual characteristics, such as genetics or lifestyle, to enhance effectiveness and reduce adverse effects. The rise in personalized medicine is propelled by its potential for more effective treatments, advances in genomics, the increasing complexity of diseases, and supportive regulations. Gene switches play a key role in personalized medicine by providing precise control over gene expression, facilitating tailored therapeutic approaches based on individual genetic profiles. For example, the Personalized Medicine Coalition reported in February 2024 that the FDA approved 16 new personalized therapies for rare diseases in 2023, up from six in 2022. This growing adoption of personalized medicine is driving the gene switch market.

In January 2023, Autolus Therapeutics, a biopharmaceutical company based in the UK, partnered with Cabaletta Bio to incorporate Autolus' RQR8 safety switch system into cell therapies aimed at autoimmune diseases. This collaboration aims to enhance the safety and effectiveness of these therapies. Cabaletta Bio, a US-based biotechnology company, is involved in developing cell therapies.

Major companies operating in the gene switch market are Bristol-Myers Squibb Company, Novartis AG, Charles River Laboratories International Inc, bluebird bio Inc., Regenxbio Inc., Kite Pharma Inc., Genomatica Inc., Intellia Therapeutics Inc., Voyager Therapeutics Inc., Precigen Inc., Editas Medicine Inc., Cellectis SA, Autolus Therapeutics plc, aceRNA Technologies, Cartherics Pty Ltd, panCELLa Inc., Aptamer Group plc, Bellicum Pharmaceuticals Inc., Genocea Biosciences Inc., CRISPR Therapeutics AG.

North America was the largest region in the gene switch market in 2023. The regions covered in the gene switch market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the gene switch market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A gene switch is a molecular tool that can activate or deactivate genes or modulate their activity levels, allowing cells to adjust gene expression in response to various signals and environmental changes. Gene switches offer precise control over gene expression, facilitating targeted therapeutic treatments, advanced research endeavors, and enhanced biotechnology processes.

The primary types of gene switches include CAR T cell therapies, gene therapies, and other methods. CAR T cell therapies involve altering a patient’s T cells, a type of immune cell, to express a receptor that targets cancer cells. The payment models for these therapies often include upfront payments and milestone payments, and they are used for managing treatment-related toxicity, regulating gene expression, and other therapeutic applications.

The gene switch market research report is one of a series of new reports that provides gene switch market statistics, including gene switch industry global market size, regional shares, competitors with a gene switch market share, detailed gene switch market segments, market trends, and opportunities, and any further data you may need to thrive in the gene switch industry. This gene switch market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gene switch market consists of revenues earned by entities by providing services such as gene regulation services, custom gene synthesis, research and development services, consulting, and support. The market value includes the value of related goods sold by the service provider or included within the service offering. The gene switch market also includes sales of synthetic gene constructs, gene switch kits, regulatory proteins and small molecules, delivery systems, assay systems, software, and bioinformatics tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.